Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

The Interleukin-33–Group 2 Innate Lymphoid Cell Axis Represents a Potential Adjuvant Target To Increase the Cross-Protective Efficacy of Influenza Vaccine

Journal of Virology(2021)10.1128/jvi.00598-21Source: DataRank Database

The Interleukin-33–Group 2 Innate Lymphoid Cell Axis Represents a Potential Adjuvant Target To Increase the Cross-Protective Efficacy of Influenza Vaccine is a research paper published in Journal of Virology (2021). On theSindex it has a DataRank of 0. It has been cited 15 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access15 citations

Download PDF

Cite:

Linked data & code

doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (9 grants)Impact (FWCI 1.03)OA: greenTopics (57)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (6)

Sreeja Biswas Roy ORCID,Danielle Califano,Andrew N. J. McKenzie ORCID,Dennis W. Metzger ORCID,Yoichi Furuya ORCID

Live enrichment

PubMed:34468174 PMC:PMC8549502 OpenAlex:https://openalex.org/W3198848201

American Heart Association

Grant: 17SDG33630188

HHS | National Institutes of Health

Grant: AI146434

HHS | National Institutes of Health

Grant: AI075312

Medical Research Council

Grant: MC_U105178805

NIAID NIH HHS

Grant: R01 AI075312

NIAID NIH HHS

Grant: R56 AI146434

American Association of Immunologists (AAI)

American Association of Immunologists

American Association of Immunologists (AAI)

FWCI

1.03

Citation Percentile

0.7%

Citation Trend

2021

2022

2023

2024

2026

greenLicense: https://doi.org/10.1128/ASMCopyrightv2

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/8549502

publisherhttps://journals.asm.org/doi/pdf/10.1128/JVI.00598-21

journalhttps://doi.org/10.1128/jvi.00598-21

repositoryhttps://pubmed.ncbi.nlm.nih.gov/34468174

Fields of Study

IL-33, ST2, and ILC PathwaysEosinophilic EsophagitisImmune Cell Function and InteractionAdjuvants, ImmunologicAnimalsAntibodies, ViralCross ProtectionFemaleImmunity, HumoralInfluenza A Virus, H1N1 SubtypeInfluenza VaccinesInterleukin-33LymphocytesMaleMiceMice, Inbred BALB CMice, Inbred C57BLMice, KnockoutOrthomyxoviridae InfectionsVaccine EfficacyVaccines, Inactivated

MeSH Terms

Interleukin-33Vaccine EfficacyAdjuvants, ImmunologicAnimalsAntibodies, ViralFemaleInfluenza VaccinesLymphocytesMaleMice, Inbred BALB CMice, Inbred C57BLOrthomyxoviridae InfectionsVaccines, InactivatedMice, KnockoutMiceInfluenza A Virus, H1N1 SubtypeImmunity, HumoralCross Protection

Keywords

BiologyImmunologyAdjuvantVirologyVaccinationImmunityImmune systemHumoral immunityVirusVaccine efficacyInfluenza A virusCytokineInfluenza vaccineInfluenzaInactivated vaccineCross-protectionIl-33Ilc2

Sustainable Development Goals

SDG 0: Good health and well-being

The Interleukin-33–Group 2 Innate Lymphoid Cell Axis Represents a Potential Adjuvant Target To Increase the Cross-Protective Efficacy of Influenza Vaccine

FAIR Checklist

Authors (6)

Funding (9 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)